Medical Condition News

RSS

Alnylam announces clinical data from patisiran Phase 2 OLE study for treatment of patients with FAP

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today initial 12-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis) in patients with familial amyloidotic polyneuropathy (FAP).

24 Apr 2015

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines and non-invasive diagnostics, today announced that its novel solid dose formulation of teriparatide (parathyroid hormone) achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Forteo/Forsteo).

24 Apr 2015

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

24 Apr 2015

Cardiff scientists make breakthrough asthma discovery

Cardiff University scientists have for the first time identified the potential root cause of asthma and an existing drug that offers a new treatment.

24 Apr 2015

New research shows that serious life events in childhood can increase type 1 diabetes risk

New research from Sweden published in Diabetologia (the journal of the European Association for the Study of Diabetes) shows that serious life events (SLEs) in childhood, such as death or illness in the family, divorce/separation, a new child or adult in the family, and conflicts in the family, can triple the risk of subsequently developing type 1 diabetes (T1D).

23 Apr 2015

VTT develops easy-to-use ketosis test that can benefit diabetics and dieters

VTT has developed a quick, easy-to-use ketosis test for consumers that can detect acetone on exhaled breath. The test will benefit diabetics and dieters in particular, but it can easily be adapted to other uses as well, such as the detection of the air pollutants formaldehyde or acetaldehyde. VTT is now seeking a partner to commercialise the product.

23 Apr 2015

Study show that silymarin may be a useful treatment for NASH

Results from a double-blind, placebo-controlled study of silymarin, which is derived from the milk thistle plant, have shown that this herbal remedy may be a useful treatment option for non-alcoholic steatohepatitis (NASH).

23 Apr 2015

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Results presented today at The International Liver Congress 2015 show that the use of the fixed-dose combination of ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) was well tolerated and demonstrated high sustained virologic response rates 12 weeks post treatment (SVR12) in patients with chronic hepatitis C virus (HCV) infection who have decompensated liver disease (cirrhosis) or have undergone liver transplantation.

23 Apr 2015

Diabetes drug liraglutide could prove to be a new treatment option for NASH

A drug approved to treat type 2 diabetes could prove to be a powerful new treatment option for non-alcoholic steatohepatitis (NASH), according to research presented today at The International Liver Congress 2015. Results from a randomised controlled trial showed liraglutide met the primary endpoint of histological clearance of NASH, and a reduction in the progression of fibrosis.

23 Apr 2015

Exome sequencing helps identify link between environmental exposures and mutational patterns in HCC

A new study presented today at The International Liver Congress 2015 shows that by using genomic analyses to understand how and when carcinogenic mutations occur in patients with hepatocellular carcinoma (HCC), it is possible to identify specific molecular profiles. It is hoped that these molecular profiles will help identify which patients would benefit from specific anticancer treatments.

23 Apr 2015

Remogliflozin etabonate: A potential treatment option for management of NASH and NAFLD

Data presented today at The International Liver Congress 2015 demonstrates that remogliflozin etabonate, an investigational drug in type 2 diabetes, is a potential treatment option for the management of patients with non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

23 Apr 2015

Non-alcoholic fatty liver disease can promote development of coronary artery calcification

Data revealed today at The International Liver Congress 2015 show that non-alcoholic fatty liver disease (NAFLD) plays a role in the early stages of coronary atherosclerosis and in its more severe form it can also promote the development of coronary artery calcification (CAC).

23 Apr 2015

Study supports use of vitamin E as effective treatment for NASH

Results revealed today at The International Liver Congress 2015 show that vitamin E (d-alpha-tocopherol) is an effective treatment for non-alcoholic steatohepatitis (NASH). NASH occurs when the liver becomes inflamed due to the accumulation of fat. Over time, persistent inflammation can lead to the formation of fibrous scar tissue in the liver and around its blood vessels, which can eventually cause cirrhosis.

23 Apr 2015

Study: Demanding jobs raise survival chances in frontotemporal dementia

People with more demanding jobs may live longer after developing the disease frontotemporal dementia than people with less skilled jobs, according to a new study published in the April 22, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology.

23 Apr 2015

Gulf Coast residents continue to struggle with the aftermath of Deepwater Horizon oil spill

Five years ago, on April 20, 2010, the BP Deepwater Horizon oil platform exploded; over the next five months, more than 206 million gallons of oil gushed into the Gulf of Mexico, affecting more than 950 miles of shoreline.

23 Apr 2015

Study shows that Hodgkin lymphoma patients can remain disease-free with just chemotherapy alone

In a paper published in the New England Journal of Medicine, the scientists show that a positron-emission tomography (PET) scan immediately after treatment with chemotherapy can identify patients who have a very good outcome without additional radiotherapy.

23 Apr 2015

Several drugs could lead to new MS treatment options

New research published this week in Nature has found several drugs could lead to new treatment options for multiple sclerosis (MS), including two drugs that effectively treat MS at the source, in vivo. When administered at the peak of disease, these two drugs showed a striking reversal of disease severity.

23 Apr 2015

New brain mapping model could improve success rate of transcranial magnetic stimulation

Brain researchers from the Perelman School of Medicine at the University of Pennsylvania have developed a new brain mapping model which could improve the success rate of transcranial magnetic stimulation (TMS) in treating conditions including depression, neuropathic pain, and stroke.

23 Apr 2015

AMP report provides overview of current research on minimally invasive 'liquid biopsy' approaches

The Association for Molecular Pathology, the premier global, non-profit organization serving molecular diagnostic professionals, today published a special article in The Journal of Molecular Diagnostics titled, "Do Circulating Tumor Cells, Exosomes, and Circulating Tumor Nucleic Acids Have Clinical Utility?" The report provides a thorough overview of research to-date on the minimally invasive "liquid biopsy" approaches to cancer diagnostics.

23 Apr 2015

ADCs based on alpha-amanatin may help treat colorectal cancer

For some time, cancer scientists have considered the toxin, alpha-amanatin derived from "death cap" mushrooms, as a possible cancer treatment. However, due to its penchant for causing liver toxicity, its potential as an effective therapy has been limited.

23 Apr 2015

Medical Condition News

Alnylam announces clinical data from patisiran Phase 2 OLE study for treatment of patients with FAP

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Cardiff scientists make breakthrough asthma discovery

New research shows that serious life events in childhood can increase type 1 diabetes risk

VTT develops easy-to-use ketosis test that can benefit diabetics and dieters

Study show that silymarin may be a useful treatment for NASH

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Diabetes drug liraglutide could prove to be a new treatment option for NASH

Exome sequencing helps identify link between environmental exposures and mutational patterns in HCC

Remogliflozin etabonate: A potential treatment option for management of NASH and NAFLD

Non-alcoholic fatty liver disease can promote development of coronary artery calcification

Study supports use of vitamin E as effective treatment for NASH

Study: Demanding jobs raise survival chances in frontotemporal dementia

Gulf Coast residents continue to struggle with the aftermath of Deepwater Horizon oil spill

Study shows that Hodgkin lymphoma patients can remain disease-free with just chemotherapy alone

Several drugs could lead to new MS treatment options

New brain mapping model could improve success rate of transcranial magnetic stimulation

AMP report provides overview of current research on minimally invasive 'liquid biopsy' approaches

ADCs based on alpha-amanatin may help treat colorectal cancer

A new method to measure intracellular water in biological systems

Obesity, GLP-1s, and metabolic care

Automation in cell-based workflows

Latest News